Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial
Authors:
- A. JakobsenAJA. Jakobsen
- P.L. FrederiksenPFP.L. Frederiksen
- K.Aa. MøllerKMK.Aa. Møller
- A.P. AndersenAAA.P. Andersen
- H. BrinckerHBH. Brincker
- P. DombernowskyPDP. Dombernowsky
- P.V. HansenPHP.V. Hansen
- I. HesseliusIHI. Hesselius
- M. KjærMKM. Kjær
- 1 September 1986
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 22 (9) , 1067-1072
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.Journal of Clinical Oncology, 1984
- Oral high-dose medroxyprogesterone acetate causes adrenal suppression in patients with breast cancerEuropean Journal of Cancer and Clinical Oncology, 1982
- Medroxyprogesterone Acetate (MPA) Plasma Levels After Oral and Intramuscular Administration in A Long‐Term StudyActa Obstetricia et Gynecologica Scandinavica, 1981
- High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapyCancer Chemotherapy and Pharmacology, 1979
- High Dose Medroxyprogesterone Acetate (MPA) Treatment in Metastatic Carcinoma of the Breast: A Dose-Response EvaluationTumori Journal, 1978